Back to all studies
CompletedNCT00483106

Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)

This study is completed. It focuses on ADHD and currently lists study information in Canada.

ADHDDrugFrom 6 Years to 12 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT00483106. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether a study medication may be useful for children experiencing ADHD.

What would participation involve?

Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Canada.

Who is it mainly for?

This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

What to expect

Your next step

The official record suggests in-person participation through a university, with sites including Douglas Mental Health University Institute in Montreal. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. Common reasons not to take part include other clinical factors that could make participation unreliable or unsafe and other factors that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: November 1999
Recruitment status
Completed
Estimated enrollment
Not clearly listed
Sponsor
McGill University
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
Canada
Age range
From 6 Years to 12 Years
Official registry ID
NCT00483106
Official title
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT00483106. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Canada.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by McGill University, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me